Regeneron Pharmaceuticals Inc. buy SVB Securities
Start price
27.03.23
/
50%
€769.90
Target price
27.03.24
€905.83
Performance (%)
16.25%
End price
28.03.24
€895.00
Summary
This prediction ended on 28.03.24 with a price of €895.00. The prediction had a final performance of 16.25%. SVB_Securities has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -3.315% | -3.315% | 30.774% | -14.953% |
| iShares Core DAX® | 2.554% | 0.562% | 14.142% | 49.144% |
| iShares Nasdaq 100 | 2.742% | -0.599% | 30.370% | 82.047% |
| iShares Nikkei 225® | 6.584% | 4.336% | 49.372% | 60.623% |
| iShares S&P 500 | 1.930% | -0.507% | 24.257% | 59.657% |
Comments by SVB_Securities for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at SVB Securities from a "market perform" rating to an "outperform" rating. They now have a $976.00 price target on the stock, up previously from $834.00.
Ratings data for REGN provided by MarketBeat
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von SVB_Securities gewählte maximale Laufzeit wurde überschritten